- Sam L. Barker, Ph.D. Elected to Board of Directors -

THE WOODLANDS, Texas, April 6 /PRNewswire/ -- Lexicon Genetics Incorporated announced today the appointment of C. Thomas Caskey, M.D. as Chairman of its Board of Directors and the election of Sam L. Barker, Ph.D. as a member of its Board of Directors.

Dr. Caskey served as Senior Vice President, Research at Merck Research Laboratories from 1995 to March 2000 and as President of the Merck Genome Research Institute from 1996 to March 2000. Before joining Merck, Dr. Caskey served 25 years at Baylor College of Medicine in a series of senior positions, including Chairman, Department of Human and Molecular Genetics and Director, Human Genome Center. He is a member of the National Academy of Sciences and holds numerous other awards and distinctions. Dr. Caskey received his B.A. from the University of South Carolina and his M.D. from Duke University Medical School.

Dr. Barker served in a series of senior domestic and international management positions at Bristol-Myers Squibb until his retirement in 1998. His positions at Bristol-Myers Squibb included service as Executive Vice President, Worldwide Franchise Management and Strategy during 1998, President, U.S. Pharmaceutical Group from 1995 to 1997 and President, U.S. Pharmaceuticals from 1992 to 1995. Dr. Barker received his B.S. from Henderson State College, his M.S. from the University of Arkansas and his Ph.D. from Purdue University.

Lexicon Genetics Incorporated (www.lexicon-genetics.com) is a pioneer in the design, development and application of high-throughput gene trapping and mutagenesis technologies for gene discovery and functional genomics. Lexicon employs its proprietary Human Gene Trap(TM) database, OmniBank(R) library of gene-trapped mouse clones and its Internet-based bioinformatics software in an integrated technology platform for drug discovery and drug target validation. Lexicon has commercial OmniBank alliances with The R.W. Johnson Pharmaceutical Research Institute, G.D. Searle & Co., Boehringer Ingelheim Pharmaceuticals, N.V. Organon, ZymoGenetics/Novo Nordisk and DuPont Pharmaceuticals, and a separate functional genomics agreement with Millennium Pharmaceuticals, Inc. Lexicon also provides access to a substantial portion of OmniBank through its www.lexgen.com genomics Internet exchange to subscribers at leading research institutions throughout the world. Lexicon Genetics Incorporated, founded in 1995, is a privately-held company based in The Woodlands, Texas, U.S.A.